Fig. 3.
Cost-effectiveness acceptability curve for mirabegron 50 mg vs tolterodine extended release 4 mg; general OAB population. OAB overactive bladder syndrome, QALY quality-adjusted life year
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.